India, Feb. 26 -- Emcure Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) had conducted a current Good Manufacturing Practices (cGMP) inspection of Company's API manufacturing facility located at M.I.D.C., Kurkumbh, Taluka - Daund, Pune - 413802, Maharashtra, from 19 February 2025 to 25 February 2025. On conclusion of the inspection, the Company received two observations in Form 483.
Published by HT Digital Content Services with permission from Pivotal Sources....